766 related articles for article (PubMed ID: 27960595)
1. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Gandhi A; Balmer P; York LJ
Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
[TBL] [Abstract][Full Text] [Related]
3. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
[TBL] [Abstract][Full Text] [Related]
5. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
[TBL] [Abstract][Full Text] [Related]
6. Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.
McNeil LK; Donald RGK; Gribenko A; French R; Lambert N; Harris SL; Jones TR; Li S; Zlotnick G; Vogel U; Claus H; Abad R; Vazquez JA; Borrow R; Findlow J; Taha MK; Deghmane AE; Caugant DA; Kriz P; Musilek M; Wang X; Vuong J; Mayer LW; Pride MW; Jansen KU; Anderson AS
mBio; 2018 Mar; 9(2):. PubMed ID: 29535195
[TBL] [Abstract][Full Text] [Related]
7. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
[TBL] [Abstract][Full Text] [Related]
8. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
[TBL] [Abstract][Full Text] [Related]
9. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
Pajon R; Lujan E; Granoff DM
Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
[TBL] [Abstract][Full Text] [Related]
10. Broad vaccine protection against Neisseria meningitidis using factor H binding protein.
Findlow J; Bayliss CD; Beernink PT; Borrow R; Liberator P; Balmer P
Vaccine; 2020 Nov; 38(49):7716-7727. PubMed ID: 32878710
[TBL] [Abstract][Full Text] [Related]
11. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
[TBL] [Abstract][Full Text] [Related]
12. Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.
Harris SL; Donald RG; Hawkins JC; Tan C; O'Neill R; McNeil LK; Perez JL; Anderson AS; Jansen KU; Jones TR
Pediatr Infect Dis J; 2017 Feb; 36(2):216-223. PubMed ID: 27846061
[TBL] [Abstract][Full Text] [Related]
13. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
[TBL] [Abstract][Full Text] [Related]
14. Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years.
Shirley M; Dhillon S
BioDrugs; 2015 Oct; 29(5):353-61. PubMed ID: 26394633
[TBL] [Abstract][Full Text] [Related]
15. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
Rossi R; Beernink PT; Giuntini S; Granoff DM
Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
[TBL] [Abstract][Full Text] [Related]
17. Use of expanded
Borrow R; Martinón-Torres F; Abitbol V; Andani A; Preiss S; Muzzi A; Serino L; Sohn WY
Expert Rev Vaccines; 2023; 22(1):738-748. PubMed ID: 37622470
[TBL] [Abstract][Full Text] [Related]
18. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
[TBL] [Abstract][Full Text] [Related]
19. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
[TBL] [Abstract][Full Text] [Related]
20. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
